Search company, investor...
Floragenex company logo

Floragenex

floragenex.com

Founded Year

2006

Stage

Acquired | Acquired

About Floragenex

Floragenex is a biotechnology company and genomics testing service provider focused on next-generation DNA sequencing, offering solutions for genomic analysis in human, plant, and animal systems. Floragenex has delivered impact results in hundreds of genomics studies focused on answering fundamental questions in genetics, ecology, evolutionary biology, and biomedical research. Floragenex technologies permit investigation of genomes for academic, governmental, and commercial researchers worldwide. Floragenex was founded in 2007 as a spin-out of the University of Oregon.

Headquarters Location

4640 SW Macadam Ave Suite 130D

Portland, Oregon, 97239,

United States

541-343-0747

Missing: Floragenex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Floragenex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Floragenex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Floragenex is included in 1 Expert Collection, including Omics.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Floragenex News

Sedia Biosciences Floragenex announce completion of merger

Oct 20, 2016

Verify here. The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com. All rights reserved. All other trademarks recognized. Copyright © 1997-2016 BioPortfolio Limited. Site developed by Alacrify Ltd .

Floragenex Frequently Asked Questions (FAQ)

  • When was Floragenex founded?

    Floragenex was founded in 2006.

  • Where is Floragenex's headquarters?

    Floragenex's headquarters is located at 4640 SW Macadam Ave, Portland.

  • What is Floragenex's latest funding round?

    Floragenex's latest funding round is Acquired.

  • Who are the investors of Floragenex?

    Investors of Floragenex include Sedia Biosciences Corporation.

  • Who are Floragenex's competitors?

    Competitors of Floragenex include Echelon Biosciences, NMS Group, BioTrove, Lead Therapeutics, Cavadis and 9 more.

Compare Floragenex to Competitors

S
Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

A
Advanced Biological Technologies

Advanced Biological Technologies is a technology device used in diabetes research and development.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

S
Stheno Corporation

Stheno develops optical detection systems for research & development and quality control monitoring for the pharmaceutical industry.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

A
Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.